LRG1 and neoplasm: Following profiling of the tumour epithelial glycoproteome, Surinova et al. validated LRG1 as a tumour-derived blood biomarker and its utility as a potential diagnostic tool for colorectal cancer (CRC) [191], confirming that tumours may themselves be a source of circulating LRG1 [183, 186].